AMEX · Biotechnology

Cybin Inc. (CYBN) Stock

$8.28 +1.22% AMEX: CYBN Healthcare

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds.

Valuation

Metric	Value
Price	$8.28
Market Cap	$413.02M
P/E Ratio	-1.67
P/B Ratio	1.50
P/S Ratio	0.00
EPS (TTM)	$-0.61
52-Week High	$10.72
52-Week Low	$4.81
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-72.37%
ROA	-58.36%
ROCE	-63.74%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	9.52

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$0	$0	$0	$0
Operating Profit	$-31.0M	$-64.0M	$-52.0M	$-79.0M	$-143.0M
Net Profit	$-32.0M	$-71.0M	$-40.0M	$-78.0M	$-113.0M
EPS	$-3221645.62	$-0.43	$-0.22	$-9.41	$-0.61
Op Margin	-3592.0%	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$92.0M	$84.0M	$54.0M	$302.0M	$259.0M
Total Liabilities	$6.0M	$6.0M	$8.0M	$10.0M	$21.0M
Cash	$64.0M	$54.0M	$17.0M	$209.0M	$135.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Faraday Future Showcases Its EAI Robot World Across Three High-Level Silicon Valley Robotics and AGI Summits, Drawing Strong Developer Interest and Advancing Its New "Four-Core Full-Stack AI" Ecosystem Strategy Business Wire · Jul 17, 2026 Netflix Reported Record Quarterly Revenue of $12.6 Billion, but Guidance Came in Below Expectations. Here’s What It Means for Investors. Motley Fool · Jul 17, 2026 HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027 PR Newswire · Jul 17, 2026 To air or not to air? Nation's TV networks struggle to find the right balance for Trump speech Associated Press · Jul 17, 2026 Altinteg Strengthens Compliance-Ready Traceability For Food Operations GlobeNewswire · Jul 17, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-19.0M	$-19.0M	$-45.0M	$-69.0M	$-101.0M
Investing Cash Flow	$-1.0M	$-1.0M	$-4.0M	$6.0M	$-4.0M
Financing Cash Flow	$6.0M	$0	$0	$0	$0
Net Cash Flow	$62.0M	$-10.0M	$-37.0M	$192.0M	$-74.0M
Free Cash Flow	$-19.0M	$-19.0M	$-46.0M	$-70.0M	$-103.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.07
EV / EBITDA	-0.07
FCF Yield	-75.57%
Quick Ratio	9.52
Interest Coverage	-49.90
Return 1Y	—
Return 3Y	—
Return 5Y	—

About Cybin Inc.

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.

Cybin Inc. is headquartered in CA.

Cybin Inc. (CYBN) stock trades at $8.28 with a market capitalization of $413.02M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.67, reflecting a net loss over the last twelve months, price-to-book of 1.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.81 and $10.72, and currently trades 22.8% below its 52-week high.

On profitability, Cybin Inc. generates a return on equity (ROE) of -72.37% (negative, reflecting a net loss), return on capital employed of -63.74%.

Official website: www.cybin.com

Cybin Inc. by the numbers, 2017–2025

Between 2017 and 2025 Cybin Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-113.0M in 2025.

On a trailing twelve-month basis to Sep '25, revenue is $0 and net profit $-94.0M.

Borrowings stand at $0, cash on hand is $83.8M, cash from operations was $-101.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -57.7% over five years, and was -47.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Cybin Inc. (CYBN) — frequently asked questions

What is Cybin Inc. (CYBN) stock price today?

Cybin Inc. (CYBN) is currently trading at $8.28, up 1.22% today.

What is CYBN P/E ratio?

Cybin Inc.'s P/E ratio is -1.67. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is CYBN return on equity (ROE)?

Cybin Inc.'s return on equity (ROE) is -72.37%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Cybin Inc.'s market cap?

Cybin Inc. has a market capitalization of $413.02M.

Does CYBN pay a dividend?

Cybin Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does CYBN carry?

Cybin Inc. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is CYBN's profit margin?

Cybin Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is CYBN in?

Cybin Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is CYBN listed on?

Cybin Inc. trades on AMEX under the ticker CYBN.

What is CYBN's 52-week range?

Over the last year Cybin Inc. has traded between $4.81 and $10.72.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Screens CYBN currently matches

On the figures above, Cybin Inc. passes the filters for 8 of our ready-made screens, among them Small Cap Stocks, Stocks Under $10, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Small Cap Stocks Stocks Under $10 Debt Free Stocks Under $100 Debt Free Stocks Stocks Under $100 Stocks Under $50 Debt to Equity Below 1 Stocks High Current Ratio Stocks

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.